ANIP — ANI PHARMACEUTICALS INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1023024 ·
Last close
$69.99
Market Cap
$1.59B
52W High
$87.76
52W Low
$67.14
ADV30
446,449
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 290,777,000 | 179,246,000 | 51,835,000 | 35,149,000 | 1,567,661,000 | 420,758,000 | 930,548,000 |
| Jun 2026 | 266,044,000 | 165,886,000 | 39,838,000 | 24,711,000 | 1,494,112,000 | 360,212,000 | 896,900,000 |
| Mar 2026 | 237,462,000 | 143,880,000 | 38,706,000 | 29,492,000 | 1,421,970,000 | 311,176,000 | 859,670,000 |
| Dec 2025 | 247,060,000 | 146,791,000 | 29,127,000 | 27,490,000 | 1,440,377,000 | 285,585,000 | 899,653,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$229,197,000
Investing CF
$-29,283,000
Financing CF
$-40,728,000
CapEx
$-29,283,000
Dividends Paid
$0
Buybacks
$-29,758,000
EPS Diluted TTM
$5.02
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$66,253,000
Inventory
$136,411,000
Receivables
$304,450,000
ST Investments
$15,590,000
EBIT TTM
$172,710,000
Pretax Income TTM
$157,838,000
Interest Exp TTM
$14,872,000
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,041,342,976
EBITDA
$235,330,000
Free Cash Flow
$184,053,504
Enterprise Value
$1,608,332,416
Total Cash
$436,966,016
Total Debt
$617,356,992
Shares Out
22,718,931
Trailing EPS
$5.03
Book Value
$29.84
ROE
20.4%
ROA
6.4%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 883,366,000 | 81,230,000 | 78,337,000 | 1,440,377,000 | 899,653,000 | 540,724,000 | 185,225,000 |
| Dec 2024 | 614,376,000 | 2,218,000 | -18,522,000 | 1,284,469,000 | 855,939,000 | 428,530,000 | 64,017,000 |
| Dec 2023 | 486,816,000 | 49,529,000 | 18,779,000 | 904,422,000 | 446,823,000 | 457,599,000 | 118,959,000 |
| Dec 2022 | 316,385,000 | -25,734,000 | -47,896,000 | 760,087,000 | 421,547,000 | 338,540,000 | -31,203,000 |
TTM Snapshot
Revenues TTM
$978,379,000
NetIncome TTM
$108,310,000
OpCashFlow TTM
—
Assets (Latest)
$1,494,112,000
Forward EPS
$10.13
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $110.00 · spot: $71.47 · call volume: 14 · put volume: 39
Expected Move to 2027-01-15:
±$8.45
(11.82%) —
implied range
$63.02 –
$79.92
· ATM straddle on $70.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| KLRA | Kailera Therapeutics, Inc. | $1.58B | $12.20 | — |
| SRPT | Sarepta Therapeutics, Inc. | $1.58B | $14.77 | — |
| NRIX | Nurix Therapeutics, Inc. | $1.56B | $14.24 | — |
| PGEN | PRECIGEN, INC. | $1.54B | $4.29 | — |
| ADRX | ADARx Pharmaceuticals, Inc. | $1.53B | $13.82 | — |
News headlines (Yahoo Finance, 1h cache)
Did Earnings Beat Just Shift ANI Pharmaceuticals' (ANIP) Investment Narrative?
2026-11-12 00:23 · Yahoo
ANIP Q3 2026 deep dive: rare disease expansion and Cortrophin bottlenecks shape outlook
2026-11-10 10:05 · Yahoo
Is ANI Pharmaceuticals (ANIP) A Bargain After Its $560m Deal?
2026-11-08 10:13 · Yahoo
ANI Pharmaceuticals (ANIP) Offers $560 Million For Rare Disease Expansion
2026-11-08 09:12 · Yahoo
Should ANI Pharmaceuticals (ANIP) Look Undervalued As Results Land And Revenue Guidance Narrows?
2026-11-08 08:09 · Yahoo
ANI Pharmaceuticals Inc (ANIP) Q3 2026 Earnings Call Highlights: Strong Revenue Growth Offset ...
2026-11-06 01:17 · Yahoo
ANI Pharma (ANIP) Q3 2026 Earnings Call Transcript
2026-11-05 20:09 · Yahoo
ANI Pharmaceuticals Q3 Earnings Call Highlights
2026-11-05 18:15 · Yahoo
ANI (ANIP) Reports Q3 Earnings: What Key Metrics Have to Say
2026-11-05 13:30 · Yahoo
ANI Pharmaceuticals (NASDAQ:ANIP) reports strong Q3 2026
2026-11-05 12:40 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.